Safe Pro Labs®

Injectable medication that combines the effects of GLP-1 and GIP hormones for the treatment of type 2 diabetes

• Our products

• Support

• Contact us

• GLP 1

Injectable medication that combines the effects of GLP-1 and GIP hormones for the treatment of type 2 diabetes

• Our products

• Support

• Contact us

• GLP 1

Injectable medication that combines the effects of GLP-1 and GIP hormones for the treatment of type 2 diabetes

• Our products

• Support

• Contact us

• GLP 1

Injectable medication that combines the effects of GLP-1 and GIP hormones for the treatment of type 2 diabetes

• Our products

• Support

• Contact us

• GLP 1

Injectable medication that combines the effects of GLP-1 and GIP hormones for the treatment of type 2 diabetes

• Our products

• Support

• Contact us

• GLP 1

CONCENTRATION

Tirzepatide

40mg/3mL

PHARMACEUTICAL FORM

Injectable solution

1 vial 40 mg of Retatrutide (lyophilized powder)

1 vial 3 ml of bacteriostatic water

1 vial 40 mg of Retatrutide (lyophilized powder)

1 vial 3 ml of bacteriostatic water

1 vial 40 mg of Retatrutide (lyophilized powder)

1 vial 3 ml of bacteriostatic water

Efficacy

Retatrutide is a triple agonist of the GLP-1, GIP, and glucagon receptors, currently under investigation by Safe Pro Labs for its potential to improve glycemic control and promote weight reduction in patients with type 2 diabetes and obesity.

Its proposed mechanism of action includes stimulation of glucose-dependent insulin secretion, suppression of glucagon (via GLP-1), enhanced lipid metabolism (via GIP), and increased energy expenditure (via glucagon receptor activation).

This combined receptor activity is designed to produce complementary effects on appetite regulation, glucose metabolism, and body weight, offering a promising multi-targeted approach currently being evaluated in clinical studies.

Dados	Finalidade	Descrição
Dados de Cadastro	Realizar o cadastro; Realizar identificação dos Usuários junto à Plataforma	Descrição detalhada dos dados de cadastro.
Dados de Atividade	Personalização da Plataforma de acordo com a experiência do usuário	Descrição detalhada dos dados de atividade.

About

Tirzepatide

About

Tirzepatide

Retatrutide is an investigational triple agonist targeting GLP-1, GIP, and glucagon receptors, under active clinical evaluation. Initial studies have shown promising outcomes in weight reduction and glycemic control in patients with obesity and type 2 diabetes.

Its multi-receptor activity offers a novel strategy in metabolic disease, combining appetite suppression, insulin modulation, and increased energy expenditure.

Developed by Safe Pro Labs, Retatrutide represents a next-generation candidate in the company’s advanced peptide platform.

The project reflects a commitment to innovative, science-based solutions targeting complex endocrine and metabolic disorders.

Retatrutide remains under regulatory review in early-phase trials, with ongoing studies evaluating safety, efficacy, and long-term therapeutic potential.

Its multi-receptor activity offers a novel strategy in metabolic disease, combining appetite suppression, insulin modulation, and increased energy expenditure.

Developed by Safe Pro Labs, Retatrutide represents a next-generation candidate in the company’s advanced peptide platform.

The project reflects a commitment to innovative, science-based solutions targeting complex endocrine and metabolic disorders.

Retatrutide remains under regulatory review in early-phase trials, with ongoing studies evaluating safety, efficacy, and long-term therapeutic potential.

Indications

Therapeutic Intent. Use is restricted to research settings or supervised pilot programs under the guidance of licensed healthcare professionals.

Dosage

The medication must be administered subcutaneously in the abdomen, thigh, or upper arm. Each vial contains 40 mg of Retatrutide, reconstituted with 3 mL of bacteriostatic water, yielding a concentration of 13.33 mg/mL.

Based on Phase 2 studies, the initial dose may begin at 1 mg to 2 mg (0.075–0.15 mL) once weekly, with gradual titration every 4 weeks in increments of 2 mg to 4 mg, as tolerated, up to a maximum of 12 mg (0.90 mL) weekly

Doses between 4 mg and 12 mg weekly demonstrated meaningful reductions in body weight and glycemic parameters over 16 to 28 weeks.

Dosage must be measured precisely using an appropriate low-volume syringe and determined by a licensed healthcare provider.

Doses between 4 mg and 12 mg weekly demonstrated meaningful reductions in body weight and glycemic parameters over 16 to 28 weeks.

Dosage must be measured precisely using an appropriate low-volume syringe and determined by a licensed healthcare provider.

Dados de Cadastro	Realizar o cadastro; Realizar identificação dos Usuários junto à Plataforma	Descrição detalhada dos dados de cadastro.
Dados de Atividade	Personalização da Plataforma de acordo com a experiência do usuário	Descrição detalhada dos dados de atividade.

Dados	Finalidade	Descrição
Dados de Cadastro	Realizar o cadastro; Realizar identificação dos Usuários junto à Plataforma	Descrição detalhada dos dados de cadastro.
Dados de Atividade	Personalização da Plataforma de acordo com a experiência do usuário	Descrição detalhada dos dados de atividade.

Drug Interactions

As a triple receptor agonist, Retatrutide may influence gastrointestinal function by delaying gastric emptying and modifying gut motility patterns. These effects may alter the rate or extent of absorption of concomitantly administered oral medications, particularly those with narrow therapeutic windows.

Adverse Reactions

Gastrointestinal adverse events were the most frequently observed in clinical studies of Retatrutide. Nausea, vomiting, diarrhea, and constipation were commonly reported, particularly during the dose-escalation period. Most events were mild to moderate in intensity and tended to resolve or diminish with continued treatment and dose stabilization.

Storage

Store the lyophilized powder at room temperature, below 30 °C. Do not freeze. Protect from light and moisture.

After reconstitution with bacteriostatic water, store the solution in a refrigerator at 2 °C to 8 °C. Use within 21 days. Discard any unused reconstituted solution after this period.

Jastreboff AM et al. Triple–Hormone–Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(3):183–195. DOI: 10.1056/NEJMoa2301986

Coskun T et al. Retatrutide, a Novel Triple Hormone Receptor Agonist: Results from a Randomized Phase 1 Trial in Adults with Obesity. The Lancet Diabetes & Endocrinology. 2022. [Study presented at scientific congresses]

Kelly AS, et al. Effects of retatrutide on body weight in adolescents with obesity: results from a phase 2 trial. [In progress / Presented at ADA 2023]

Jastreboff AM et al. Triple–Hormone–Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(3):183–195. DOI: 10.1056/NEJMoa2301986

Kelly AS, et al. Effects of retatrutide on body weight in adolescents with obesity: results from a phase 2 trial. [In progress / Presented at ADA 2023]

Jastreboff AM et al. Triple–Hormone–Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(3):183–195. DOI: 10.1056/NEJMoa2301986

Kelly AS, et al. Effects of retatrutide on body weight in adolescents with obesity: results from a phase 2 trial. [In progress / Presented at ADA 2023]

Safe Pro Labs™ is a biotechnology laboratory dedicated to metabolic innovation through peptides. Our compounds are formulated for licensed medical use. No sales or prescriptions are conducted through this site.

Helpful links

Find your local office

USA

Germany

Latin America

Data Privacy